Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
How long can you delay the start of antiresorptive therapy after completion of anabolic therapy in patients with severe osteoporosis and recent invasive dental procedures?
Related Questions
Would you favor oral bisphosphonates over intravenous formulations for patients with hormone sensitive prostate cancer and androgen deprivation therapy (ADT) related osteopenia?
In asymptomatic patients with mild CKD, PTH independent hypercalcemia, and hypercalciuria—after excluding common causes such as hyperparathyroidism, vitamin D abnormalities, multiple myeloma, thyroid disease, vitamin A excess, and antacid use—what is the next best step in evaluation?
Is there a target alkaline phosphatase level for hypophosphatasia patients on asfotase alfa therapy?
Do you recommend the use of albumin-adjusted calcium measurement formulas to accurately assess calcium levels?
What patient factors are most important when considering who needs a broader workup for osteoporosis prior to starting therapy?
What can cause a vertebra to be hyperdense on bone density testing and thus excluded other than vertebral fracture or degenerative change?
Does cinacalcet reduce hypercalciuria in primary hyperparathyroidism?
Do you temporarily hold diuretics when measuring 24-hour urine calcium levels in the evaluation of primary hyperparathyroidism?
Does parathyroidectomy for primary hyperparathyroidism provide metabolic benefits, such as lowering diabetes or cardiovascular disease risk?
What is the recommended workup for PTH-independent hypercalcemia secondary to an elevated 1,25-dihydroxyvitamin D level?
